Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Johnson & Johnson NYSE: JNJ. In a filing disclosed on May 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in Johnson & Johnson stock on May 5th. The trade occurred in the Representative's "MARJORIE IRA" account.
Representative Marjorie Taylor Greene also recently made the following trade(s):
- Purchased $1,001 - $15,000 in shares of AbbVie NYSE: ABBV on 5/5/2025.
- Purchased $1,001 - $15,000 in shares of Occidental Petroleum NYSE: OXY on 5/5/2025.
- Purchased $1,001 - $15,000 in shares of Paychex NASDAQ: PAYX on 5/5/2025.
- Purchased $1,001 - $15,000 in shares of MercadoLibre NASDAQ: MELI on 5/5/2025.
- Purchased $1,001 - $15,000 in shares of Starbucks NASDAQ: SBUX on 5/5/2025.
- Purchased $1,001 - $15,000 in shares of BP NYSE: BP on 5/5/2025.
- Purchased $1,001 - $15,000 in shares of Gilead Sciences NASDAQ: GILD on 5/5/2025.
- Purchased $1,001 - $15,000 in shares of BHP Group NYSE: BHP on 5/5/2025.
- Purchased $1,001 - $15,000 in shares of Advanced Micro Devices NASDAQ: AMD on 5/5/2025.
- Purchased $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOG on 5/5/2025.
Johnson & Johnson Stock Performance
Shares of JNJ stock traded down $1.68 during mid-day trading on Friday, reaching $153.98. The stock had a trading volume of 6,519,728 shares, compared to its average volume of 7,891,472. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The firm has a market cap of $370.49 billion, a price-to-earnings ratio of 23.15, a PEG ratio of 2.56 and a beta of 0.42. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The business's fifty day moving average is $157.89 and its 200-day moving average is $154.37.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. On average, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.
Johnson & Johnson Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a yield of 3.38%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's payout ratio is currently 57.84%.
Analyst Ratings Changes
Several research firms have commented on JNJ. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Benchmark upgraded Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Barclays reduced their price target on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Argus upgraded Johnson & Johnson to a "strong-buy" rating in a research report on Friday, January 24th. Finally, Morgan Stanley lifted their target price on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a report on Wednesday, April 16th. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and an average target price of $171.82.
Check Out Our Latest Research Report on JNJ
Hedge Funds Weigh In On Johnson & Johnson
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Principal Financial Group Inc. boosted its stake in Johnson & Johnson by 10.5% during the third quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company's stock worth $562,723,000 after buying an additional 329,473 shares during the last quarter. Nordea Investment Management AB boosted its holdings in Johnson & Johnson by 13.7% in the 4th quarter. Nordea Investment Management AB now owns 6,424,675 shares of the company's stock valued at $926,438,000 after purchasing an additional 775,490 shares during the last quarter. Pensionfund Sabic grew its stake in shares of Johnson & Johnson by 49.2% in the 4th quarter. Pensionfund Sabic now owns 27,300 shares of the company's stock valued at $3,948,000 after buying an additional 9,000 shares during the period. Capital Market Strategies LLC increased its holdings in shares of Johnson & Johnson by 5.8% during the 4th quarter. Capital Market Strategies LLC now owns 7,723 shares of the company's stock worth $1,117,000 after buying an additional 425 shares during the last quarter. Finally, Canandaigua National Trust Co of Florida raised its position in shares of Johnson & Johnson by 13.2% during the 4th quarter. Canandaigua National Trust Co of Florida now owns 2,250 shares of the company's stock valued at $325,000 after buying an additional 263 shares during the period. Hedge funds and other institutional investors own 69.55% of the company's stock.
Insider Buying and Selling
In related news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Robert J. Decker sold 6,999 shares of the company's stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.
About Representative Greene
Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia's 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.
Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia's 14th Congressional District. She declared candidacy for the 2026 election.
About Johnson & Johnson
(
Get Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Featured Stories
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
